BioCryst Pharmaceuticals Inc (NASDAQ:BCRX)
| 6.09 Delayed Data As of Dec 04 |  +0.95 / +18.50%Today’s Change | 1.58 Today|||52-Week Range 6.29 | +76.38% Year-to-Date |
Latest BCRX News | Press Releases
| Why BioCryst Stock Is Crushing It Today Dec 04 / MotleyFool.com - Paid Partner Content | Are Options Traders Betting on a Big Move in BioCryst Pharmaceuticals (BCRX) Stock? Dec 03 / Zacks.com - Paid Partner Content |
| BioCryst (BCRX) Wins FDA Approval for HAE Drug Orladeyo Dec 04 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 5.14 |
| Today’s open | 5.85 |
| Day’s range | 5.75 - 6.24 |
| Volume | 1,747,670 |
| Average volume (3 months) | 5,784,249 |
| Market cap | $904.0M |
Data as of 7:33pm ET, 12/04/2020
Growth & Valuation
| Earnings growth (last year) | +4.00% |
| Earnings growth (this year) | -2.99% |
| Earnings growth (next 5 years) | +19.86% |
| Revenue growth (last year) | +136.45% |
| P/E ratio | NM |
| Price/Sales | 8.17 |
| Price/Book | 20.62 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ARVNArvinas Inc | +1.84 | +7.31% |
| CGENCompugen Ltd | -0.09 | -0.70% |
| BTAIBioXcel Therapeutics... | +0.20 | +0.44% |
| NKNantKwest Inc | +0.24 | +2.61% |
Data as of 3:59pm ET, 12/04/2020
Financials
| Next reporting date | February 24, 2021 |
| EPS forecast (this quarter) | -$0.22 |
| Annual revenue (last year) | $48.8M |
| Annual profit (last year) | -$108.9M |
| Net profit margin | -222.99% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Durham, North Carolina |
Forecasts
